-
Tytuł:
-
Determinants of Weight Evolution Among HIV-Positive Patients Initiating Antiretroviral Treatment in Low-Resource Settings.
-
Autorzy:
-
Huisin ʼt Veld D; Department of Epidemiology and Social Medicine, University of Antwerp, Antwerp, Belgium; †Clinical Sciences Department, Institute of Tropical Medicine, Antwerp, Belgium; ‡Department of Epidemiology and Biostatistics Fonds Wetenschappelijk Onderzoek-Vlaanderen, Aspirant Mandate Holder, FWO, Brussels, Belgium; §Université Bordeaux, ISPED, Centre INSERM U897-Epidémiologie-Biostatistique, Bordeaux, France; ‖ISPED, Centre INSERM U 897-Epidemiologie-Biostatistique, University of Bordeaux, Bordeaux, France; ¶Kirby Institute University of New South Wales and Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia; #Department of Biostatistics, Indiana University School of Public Health, Indianapolis, IN; **Department of Medicine, Moi University/Ampath, Eldoret, Kenya; ††Africa Centre for Health and Population Studies, University of KwaZulu-Natal, Somkhele, South Africa; ‡‡Department of Infection and Population Health, University College London, London, United Kingdom; §§Centre for Global Health & Development, Boston University, Boston, MA; ‖‖Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; ¶¶Centre de prise en charge de recherche et de formation (CePReF), Hôpital Yopougon Attié, Abidjan, Côte d'Ivoire; ##The Aurum Institute, Johannesburg, South Africa; ***Centre for AIDS Research, John Hopkins University, Baltimore, MD; †††Division of Infectious Diseases, Department of Medicine, University of Stellenbosch and Tygerberg Academic Hospital, Cape Town, South Africa; ‡‡‡Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland; §§§Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa; and ‖‖‖RTI International, Research Triangle Pa
Balestre E
Buyze J
Menten J
Jaquet A
Cooper DA
Dabis F
Yiannoutsos CT
Diero L
Mutevedzi P
Fox MP
Messou E
Hoffmann CJ
Prozesky HW
Egger M
Hemingway-Foday JJ
Colebunders R
-
Corporate Authors:
-
International Epidemiologic Databases to Evaluate AIDS (IeDEA)
-
Źródło:
-
Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2015 Oct 01; Vol. 70 (2), pp. 146-54.
-
Typ publikacji:
-
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins, Inc., c1999-
-
MeSH Terms:
-
Anti-HIV Agents/*adverse effects
Anti-HIV Agents/*therapeutic use
Body Weight/*drug effects
HIV Infections/*drug therapy
Adolescent ; Adult ; Anti-HIV Agents/administration & dosage ; Female ; Humans ; Male ; Poverty ; Young Adult
-
References:
-
Lancet Infect Dis. 2006 Jan;6(1):53-9. (PMID: 16377535)
Trans R Soc Trop Med Hyg. 2007 Aug;101(8):793-8. (PMID: 17467756)
Antivir Ther. 2007;12(5):753-60. (PMID: 17713158)
HIV Med. 2008 Mar;9(3):142-50. (PMID: 18218001)
AIDS. 2009 Apr 27;23(7):853-61. (PMID: 19287299)
Ann Trop Med Parasitol. 2010 Jan;104(1):81-90. (PMID: 20149295)
J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):507-13. (PMID: 19730111)
Trans R Soc Trop Med Hyg. 2010 Dec;104(12):751-7. (PMID: 20889179)
Antivir Ther. 2011;16(4):605-9. (PMID: 21685549)
S Afr Med J. 2011 Sep;101(9):645-50. (PMID: 21920157)
S Afr Med J. 2011 Dec;101(12):887-90. (PMID: 22273031)
Antivir Ther. 2012;17(7):1281-9. (PMID: 22951353)
Int J Epidemiol. 2012 Oct;41(5):1256-64. (PMID: 21593078)
J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):600-5. (PMID: 23023101)
AIDS Res Hum Retroviruses. 2013 Mar;29(3):435-40. (PMID: 23072344)
Am J Clin Nutr. 2013 Jun;97(6):1278-87. (PMID: 23636235)
-
Grant Information:
-
UO1AI069911-08 United States AI NIAID NIH HHS; UL1 TR001108 United States TR NCATS NIH HHS; U01 AI069911 United States AI NIAID NIH HHS; U01AI069919 United States AI NIAID NIH HHS; P30 AI027763 United States AI NIAID NIH HHS; U01 AI069919 United States AI NIAID NIH HHS; U01 AI069907 United States AI NIAID NIH HHS; K01AI083097 United States AI NIAID NIH HHS; K01 AI083097 United States AI NIAID NIH HHS; U01 AI069924 United States AI NIAID NIH HHS
-
Substance Nomenclature:
-
0 (Anti-HIV Agents)
-
Entry Date(s):
-
Date Created: 20150917 Date Completed: 20151215 Latest Revision: 20220408
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC4576726
-
DOI:
-
10.1097/QAI.0000000000000691
-
PMID:
-
26375465
-
Background: In resource-limited settings, clinical parameters, including body weight changes, are used to monitor clinical response. Therefore, we studied body weight changes in patients on antiretroviral treatment (ART) in different regions of the world.
Methods: Data were extracted from the "International Epidemiologic Databases to Evaluate AIDS," a network of ART programmes that prospectively collects routine clinical data. Adults on ART from the Southern, East, West, and Central African and the Asia-Pacific regions were selected from the database if baseline data on body weight, gender, ART regimen, and CD4 count were available. Body weight change over the first 2 years and the probability of body weight loss in the second year were modeled using linear mixed models and logistic regression, respectively.
Results: Data from 205,571 patients were analyzed. Mean adjusted body weight change in the first 12 months was higher in patients started on tenofovir and/or efavirenz; in patients from Central, West, and East Africa, in men, and in patients with a poorer clinical status. In the second year of ART, it was greater in patients initiated on tenofovir and/or nevirapine, and for patients not on stavudine, in women, in Southern Africa and in patients with a better clinical status at initiation. Stavudine in the initial regimen was associated with a lower mean adjusted body weight change and with weight loss in the second treatment year.
Conclusions: Different ART regimens have different effects on body weight change. Body weight loss after 1 year of treatment in patients on stavudine might be associated with lipoatrophy.
